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Summary 
Cytotoxicity mediated by natural killer (NK) and lymphokine-activated killer (LAK) cells may 
be of significance in host defense against viral infections. This study included 347 patients in- 
fected with human immunodeficiency syndrome virus (HIV) type 1 and 110 controls. The NK 
cell activity, either unstimulated or stimulated with interferon-tx (IFN-tx) or interleukin-2 (IL2), 
and the LAK cell activity were suppressed in patients, but the NK/LAK  cell activity did not 
differ between patients with AIDS and patients without AIDS. However, the IFN-ol-stimulated 
NK cell activity and LAK cell activity were reduced in patients with symptoms of HIV disease 
(CDCIV) when compared with asymptomatic patients (CDCII + III). When the data were ana- 
lyzed by multiple linear regression, the percentage of CD4 + cells had a positive effect on these 
two  parameters  in  patients  without  AIDS,  whereas the percentage of CD4 +  cells  had  no 
significant effect on unstimulated and IL-2-stimulated NK cell activity in these patients. In con- 
trois and AIDS patients, the percentage of CD4 + cells had no effect on NK/LAK  cell activity 
in multiple linear models. The total number of CD16 § cells was low in patients compared to 
controls, whereas the percentages of CD16 +, CD56 +, and CD16 +  CD56 + were either normal 
or elevated. Therefore, the decrease in NK cell subpopulations did not contribute to the observed 
depression in NK/LAK cell activity in vitro. It is concluded that natural immunity is suppressed 
in HIV-seropositive patients primarily because of a qualitative defect of the NK/LAK cells. This 
qualitative defect includes a reduced responsiveness to IFN-c~, which is progressive until the onset 
of symptoms, and possibly related to the loss  of CD4 + cells. 
I 
nfection with HIV type 1 causes progressive immunosup- 
pression (1-3).  This includes suppression of the natural 
immunity mediated by NK cells (4-12)  and their in vitro 
counterparts, LAK cells  (13-17). 
NK calls are CD3-  large granular lymphocytes that ex- 
press characteristic NK cell markers such as CD16 and CD56; 
a  subpopulation  expresses  CD8  (18).  They mediate non- 
MHC-restricted cytotoxicity and offer potential resistance to 
viral opportunistic infections mediated by EBV, CMV, herpes 
simplex, and herpes zoster virus (19). They also mediate cyto- 
toxic activity against malignant cells and may mediate resis- 
tance against AIDS-associated tumors such as Kaposi's  sar- 
coma (18). The in vitro-generated LAK cells show a broader 
range of non-MHC-restricted target killing (20). 
The clinical significance and the mechanism of HIV-induced 
loss of natural immunity are not fully understood, The im- 
paired NK cell activity is observed on the clonal level and 
is related to defects both at the target and postbinding levels 
(5). It is not dear whether the suppressed NK and LAK cell 
activity in HIV-seropositive subjects is caused by mainly low 
percentage, altered phenotypic appearance, or decreased func- 
tion of NK cells  (6,  10,  12). 
The aim of this study was by use of a large study material 
to test whether NK and LAK cell activity were related to 
(a) expression of NK cell related cell markers; (b) prognostic 
markers of HIV infection; and (c) clinical outcome 0udged 
by occurrence of AIDS and presence of herpes virus infec- 
tions and malignancy). 
Materials and Methods 
Patients.  347 HIV-infected patients agreed to participate in the 
study; 308 (86%) were male and the median age was 39 yr (quar- 
tiles = 33-47 yr). Of all the patients, 266 were homo- or bisexual 
males, 54 were infected through heterosexual contact, 9 were drug 
addicts, 6 were hemophiliacs, 10 were infected by blood transfu- 
sions, and 9 had unknown risk factors (7 patients had more than 
one risk factor). 110 (32%) patients had AIDS, AIDS-defining  symp- 
toms were Pneumocystis  ca~inii pneumonia (PCP) in 55 patients, can- 
didadiasis of the esophagus, trachea, bronchi, or lungs in 26, Kaposi's 
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infection in 11, HIV wasting syndrome in 8, disseminated  atypical 
mycobacteriosis in 6, and other AIDS-defining events in 23. Patients 
were further subclassified by use of The Center for Disease Con- 
trol (CDC) 1 system of classification.  132 asymptomatic patients 
were  classified  into  CDC  group  II  and  CDC  group  III 
(CDCII+III), whereas 215 patients with symptoms related to HIV 
infection were classified to CDC group IV (CDCIV). A control 
group of 110 HIV-seronegative subjects  (89% males) not at risk 
for HIV infection with a median age of 39 yr (quartiles  =  33-49 
yr) was used for comparison. 
Blood Sampling and Isolation of Blood Mononuclear Cells (BMNC). 
60 ml of blood was drawn from each  subject  and BMNC were 
isolated by density gradient centrifugation (Lymphoprep; Nyegaard, 
Oslo, Norway) on LeucoSep tubes (Greiner, Frickenhausen, Ger- 
many) and washed three times in medium RPMI 1640 (GIBCO 
BILL, Gaithersburg, MD). Calls were frozen in freezing medium 
(50%  RPMI,  30%  FCS  [GIBCO BRL],  20%  DMSO  [Bie & 
Berntsen, Rcdovre, Denmark]) and were kept in liquid nitrogen 
until thawed for analysis. 
Some patients had so few cells that it was impossible to analyze 
all of the immune markers. 
Determination of NK Cell Activity.  NK cell activity was mea- 
sured using K562 target cells in a SlCr release assay. BMNC were 
thawed and incubated for 1 h at 37~  with: (a) medium; (b) 103 
IU/ml IFN-c~ (kindly provided by Dr. Robert Jordal, The Blood 
Bank, Copenhagen County Hospital, Gentofte, Denmark); (c) 20 
IU/ml IL-2 (Boehringer Mannheim GmbH, Mannheim, Germany). 
Triplicates of 100 t~l effector cells in their incubation medium and 
100/zl target calls (105 cells per ml) were incubated in microtiter 
plates for 4 h at 37~  Unstimulated effector cells were added in 
different concentrations, E/T ratios of 100:1, 50:1, 25:1, and 12.5/, 
whereas IL-2- and IFN-c~-stimulated effector cells were used at an 
E/T ratio of 50:1. The plates  were centrifuged for 10 min;  100 
/zl supernatant was transferred to new tubes and radioactivity was 
determined. Spontaneous release was determined by incubation of 
100/~1 target cells with 100/~1 medium and maximum release by 
incubation of 100/~1 target cells plus 100/~1 medium with 10% 
Triton X-IO0. Percentage of S~Cr release (NK cell activity) was de- 
termined by the equation 
percent of lysis  (test-spontaneous)cpm 
=  x  100, 
(maximum-spontaneous)cpm 
and was given as mean of triplicates.  For subjects  with NK cell 
activity >5%  (214 patients, 91 controls) lyric units (LUgs) were 
calculated.  One LUls is the number of effector cells required to 
achieve 15% cytotoxicity of K562 as derived from a titration curve 
of twofold serial dilutions of effector cells. One LUls/106 CD16 § 
ceUs is the number of LU1s in 106 CD16 + cells. In each assay, three 
preparations of cryopreserved BMNC obtained from buffy coats 
were also analyzed. Whenever two out of three control prepara- 
tions were outside their normal range (mean +_ 2 SD), the assay was 
rejected. On average, SlCr spontaneous  release never exceeded 15% 
and was 8% of maximum release. Three controls and six patients 
(three non-AIDS, three AIDS) had NK cell activity measured by 
use of fresh and frozen BMNC of the same blood sample. Frozen 
cells had in general a slightly reduced cytotoxic activity; the effect 
differed between assays, whereas the relative decrease was similar 
in patients and controls (data  not shown). 
1 Abbreviations used in this paper'. BMNC, blood mononuclear cells; CDC, 
Center for Disease Control; LU15; lytic units. 
Determination of LAK Cell Activity.  After thawing, BMNC were 
incubated with 6,000 IU/ml IL-2 (Proleukin; Eurocetus B.V., Am- 
sterdam, The Netherlands) for 48 h at 37~  LAK activity was 
measured in a SlCr release assay using DAUDI target cells. 100 #1 
LAK cell suspension  and 100/~1 target cells (2 x 104 cells per ml) 
were added to each well in microtitre plates. LAK ceils were added 
in different concentrations giving E/T ratios of 50:1, 25:1, 12.5:1, 
and 6.25:1. Otherwise the SlCr release assay was performed as de- 
scribed for the NK cell assay. Cryopreserved control preparations 
were made and used as already described.  On average, the sponta- 
neous release of SlCr never exceeded 25% and was  11% of max- 
imum release. 
Clinical Chemical Tests.  Leukocyte, lymphocyte, and neutrocyte 
concentrations were determined using a cell counter (Technicon 
H.1; Miles Inc., Tarrytown, NY). Antibodies to HIV were assessed 
using an ELISA and confirmed by the Western blot method. HIV- 
p24 antigen was detected with a sandwich-type immunoassay that 
used murine mAb (anti-HIV core antigen) coated onto microwell 
strips (Coulter Corp., Hialeah,  FL). Serum B2-microglobulin con- 
centrations were measured with a quantitative competitive enzyme 
(Pharmacia Diagnostics, Piscataway,  NJ). 
FACS |  Analysis.  PE-conjugated mAbs IgG1, Leu-2a (CD8), 
Leu-M3 (CD14), and Leu-19 (CD56) (Becton Dickinson and Co., 
Mountain View, CA) and fluorescein-conjugated mAbs IgG1, Leu-4 
(CD3), Leu-2 (CD4), and Leu-lla (CD16) (Becton Dickinson) were 
used. Frozen mononuclear cells were thawed and washed twice in 
PBS with 2% FCS. 10  s cells were resuspended in 100/zl PBS con- 
taining FCS and incubated for 30 rain at 5~  with 10/~1 of one 
or two mAbs. Labeled cells were washed three times and analyzed 
by flow cytometry using a FACStar |  (Becton Dickinson).  The 
mononuclear cells were incubated with antibodies to CD16 in com- 
bination with CD8 and CD16 in combination with CD56. PE- 
and fluorescein-conjugated  mouse IgG1 was used as a negative con- 
trol. Lymphocytes were distinguished from monocytes by their for- 
ward vs right angle light scatter.  The monocyte-specific reagent 
CD14 was used to test for monocyte contamination of lympho- 
cytes. On average, the proportion of CD14 § cells within the lym- 
phocyte gate was 2.6% for the patient group and 1.7% for con- 
trois.  In patients,  fresh and frozen BMNC were independently 
analyzed for expression of CD4. Three controls and three patients 
had a complete FACS  |  (Becton Dickinson) analysis performed on 
fresh and frozen cells. Freezing did not change the composition 
of lymphocyte subsets  in neither group (data  not shown). 
Statistical Analysis.  Since the data did not have a normal distri- 
bution, they are presented as medians,  1. and 3. quartiles.  Groups 
were compared by rank sum tests with P  =  0.05 as the significance 
level. Initially, NK/LAK cell activity was compared between groups 
at an E/T ratio of 50:1, and only if this was significant,  other E/T 
ratios were compared. Correlations and multiple linear regression 
were used to examine relations between different markers within 
each group, BMDP (Los Angeles,  CA) and SYSTAT (Evanston, 
IL) statistical  software were used. 
Results 
NK and LAK  Cell Activity.  Unstimulated NK cell activ- 
ity expressed at E/T ratios of 100:1, 50:1, 25:1, or 12.5:1 was 
suppressed in the patients compared to controls (P <10-9 in 
all E/T ratios; Fig. 1). Unexpectedly, no difference was found 
between patients with AIDS and patients without AIDS (P = 
0.9 at an E/T ratio of 50:1; Fig. 1). Furthermore, there was 
no difference between CDCII+III patients and CDCIV pa- 
tients (P =  0.2 at an E/T ratio of 50:1; Table 1) or between 
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lymphoma,  or herpes  virus  infections  (data  not  shown). 
The LAK cell activity was lower in patients than in con- 
trols  (P  <10 -9  in  all  E/T  ratios),  but  no  difference  was 
found between patients with AIDS and patients without AIDS 
(P  =  1 at an E/T ratio of 50:1; Fig.  2). Patients  in CDCIV 
had lower LAK cell activity in E/T ratio 50:1 and E/T ratio 
Filpn'r  1.  NK cell activity. Percentage of Cr release 
of IC562 target ceils at E/T ratios 100:1, 50:.1, 25:1, and 
12.5:1. Controls, n =  98; patients, n -  287; non-AIDS, 
n  =  213; AIDS, n  z  74.  *Significantly different from 
controls (P <10-9). 
25:1 compared to patients in CDCII + III (Table 1). NK cell 
activity stimulated by I1:2 or IFN-c~ was reduced in patients 
compared to controls,  whereas patients with AIDS had similar 
activity as patients without AIDS (Table 2).  It also appears 
from Table 2 that the NK cell activity evaluated by percentage 
of lysis of target cells was boosted with II.-2 to the same ex- 
tend in patients and controls, whereas there was an impaired 
Table  1.  Comparison of NK Cell and LAK Cell Activity between CDC Groups 
CDCII +llI  CDCIV  Comparison  of 
(n  =  132)  (n  =  215)  groups 
NK cell activity (percentage  of lysis)  9  8  P  =  0.2 
Unstimulated  (E/T  =  50:.1)  (4-16)  (4-13) 
NK  cell activity  (Percentage  of lysis) 
IL-2 stimulated  (E/T  =  50:1) 
Difference 
(Stimulated-unstimulated) 
NK  cell activity  (percentage  of lysis) 
IFN-o~ stimulated  (E/T  =  50:1) 
Difference 
(Stimulated-unstimulated) 
LAK cell activity (percentage  of lysis) 
(E/T)  =  50:1 
LAK cell activity (percentage  of lysis) 
(E/T)  =  25:1 
16  13  P  =  0.08 
(7-25)  (6-22) 
5  3  P  =  0.3 
(0-11)  (1-9) 
17  12  P  =  0.02 
(7-25)  (6-19) 
6  3  P  (0.0001 
(2-10)  (0-7) 
33  24  P  =  0.02 
(19-46)  (12-42) 
24  22  P  =  0.05 
(12-42)  (9-34) 
Median, quartiles, and P  values  are shown. 
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in CDCIV had reduced IFN-cz-stimulated NK cell activity 
when compared to patients in CDCII+III, whereas the IL- 
2-stimulated NK cell activity did not differ between these 
two subgroups (Table  1). 
Lymphocyte Su~opulations,  The percentages  of CD16 + 
and CD16 +  CD56 + cells did not differ between patients and 
controls  (P  =  0.3  vs  P  --  0.2),  but  the percentages  of 
CD56 + and CD16 +  CD8 + NK cell subtypes were higher in 
patients compared to controls (P <0.0001).  The percentage 
of CD16 +  CD8 + ceils did not differ between patients with 
AIDS and patients without AIDS (P  =  0.3), but the per- 
centages  of all other NK cell subtypes were higher in the 
AIDS group compared to the non-AIDS group (P <0.0001). 
The total concentrations of CD16 + and CD16 +  56 + cells 
Figure 2.  LAK cell activity. Percentage of Cr release 
ofK562 target cells at E/T ratios 50:1, 25:1, 12.5:1, and 
6.25:1. Controls, n = 94; patients, n -  258; non-AIDS, 
n  =  201; AIDS, n  -  57. *Significantly different from 
controls  (P <10-9). 
were lower in patients compared to controls (P  =  0.0007 
vs P  =  0.0003),  whereas the total concentration of CD56 + 
cells did not differ between patients and controls (P  =  1.0) 
and the concentration of CD16 +  CD8 + cells was elevated in 
the patient group (P  =  0.0004).  The total concentrations 
of all NK cell subsets  were suppressed  in the AIDS group 
compared to the non-AIDS group  (Table 3). 
The percentage and absolute number of CD8 + cells were 
elevated in patients compared to controls. There was a slight 
increase in the percentage of CD8 + cells in the AIDS group 
compared to the non-AIDS group, whereas the total number 
of  CD8 +  cells  was  twofold  increased  in  the  non-AIDS 
group compared to the AIDS group (Table 3). The percentage 
of CD3 + cells did not differ between patients and controls, 
whereas the total concentration of CD3 + cells was lower in 
Table 2.  Analysis of lL-2- and IFN-ot-stimulated NK Cell Activity 
(c)  (p)  (N)  (A) 
n  =  97  n  =  237  n  =  195  n  =  42  C  vs P  N  vs A 
NK cell activity (percentage of lysis)  25  14  13  16  P  <0.0001  P  =  0.09 
(IL-2 stimulated)  (11-36)  (6-23)  (6-22)  (8-26) 
Difference  5  4  4  5  P  =  0.61  P  =  0.21 
(Stimulated-unstimulated)  (0-13)  (1-10)  (0-10)  (1-12) 
NK cell activity (percentage of lysis)  33  13  13  15  P  <0.0001  P =  0.06 
(IFN-c~  stimulated)  (21-47)  (6-24)  (6-24)  (11-19) 
Difference  15  4  5  3  P  <0.0001  P  =  0.11 
(Stimulated-unstimulated)  (9-21)  (1-8)  (1-9)  (0-6) 
Median,  quartiles,  and P  values are shown. All NK/LAK cell activities are at E/T ratio 50:1.  C, controls; P, patients;  N, non-AIDS; A, 
AIDS. 
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C  P  N  A 
(n  =  106)  (n  =  325)  (n  =  223)  (n  =  102) 
Comparison  of groups  Correlation  to 
percent  of CD4* 
C  vs P  N  vs A  (P  only) 
CD  16 § 
Percentage  9.1  10.0  9.3  12.0 
(6.6-13.7)  (6.6-15.9)  (6.1-14.9)  (8.0-17.5) 
Concentration  179  120  149  90 
(cells per mm  3)  (103-271)  (73-230)  (89-258)  (44-155) 
CD56 + 
Percentage  6.1  8.9  8.3  10.7 
(4.1-9.7)  (5.7-14.1)  (5.4-12.9)  (7.4-17.3) 
Concentration  115  114  129  74 
(cells per mm  3)  (69-169)  (55-208)  (73-220)  (36-190) 
CD 16 +  CD56 § 
Percentage  2.4  2.9  2.5  3.6 
(1.1-4.4)  (1.2-5.2)  (1.0-4.9)  (1.7-6.4) 
Concentration  41  33  38  23 
(cells per mm  3)  (21-88)  (13-71)  (17-75)  (9-61) 
CD16+CD8 + 
Percentage  0.7  1.6  1.5  1.7 
(0.3-1.4)  (0.9-2.9)  (0.9-2.7)  (0.9-3.4) 
Concentration  13  21  23  12 
(cells per mm  3)  (5-25)  (9-40)  (13-47)  (5-29) 
CD8 § 
Percentage  22.2  42.6  40.9  46.9 
(17.5-26.8)  (33.1-53.1)  (33.0-50.7)  (33.9-57.0) 
Concentration  386  531  633  310 
(cells per mm  3)  (255-562)  (346-831)  (434-915)  (157-556) 
CD3 § 
Percentage  62.0  62.8  64.8  56.4 
(50.2-69.5)  (51.8-71.9)  (54.0-72.4)  (45.0-69.4) 
Concentration  1,077  810  1,002  390 
(cells per mm  3)  (826-1421)  (468-1236)  (681-1364)  (230-630) 
CD4 + * 
Percentage  37,9  13.7  17.9  3.7 
(31.0-42.2)  (4.5-23.0)  (11,9-25.0)  (2.1-8.5) 
Concentration  677  190  286  34 
(cells per mm  3)  (496-925)  (46-363)  (170-462)  (11-66) 
P  =  0.3  P  =  0.006  P  =  0.002 
r  =  -0.17 
P  =  0.0007  P  <0.0001  P  =  0.1 
r  =  0.08 
P  <0.0001  P  =  0.0003 
P  =  1.0  P  =  0.0001 
P  =  0.2  P  =  0.002 
P  =  0.003  P  =  0.006 
P  <0.0001  P  =  0.3 
P  =  0.0004  P  <0.0001 
P  <0.0001  P  =  0.02 
P  <0.0001  P  <0.0001 
P  =  0.6  P  =  0.0001 
P  <0.0001  P  <0.0001 
P  <0.0001  P  <0.0001 
P  <0.0001  P  <0.0001 
P  =  0.001 
r  ~=  -0.26 
P  =  0.9 
r  =  0.01 
P  =  0.008 
r  =  -0.15 
P  =  0.4 
r  =  0.05 
P  =  0.003 
r  =  -0.17 
P  =  0.6 
r  =  0.03 
P  =  0.001 
r  =  -0.21 
P  =  0.2 
r  =  0.08 
P  =  0.001 
r  --  0.30 
P  <0.001 
r  =  0.305 
P  <0.0001 
r  =  0.88 
P  <0.0001 
r  =  0.75 
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continued Table  3.  Continued 
C  P  N 
(n  =  106)  (n  =  325)  (n  =  223) 
Comparison  of groups  Correlation  to 
A  percent  of CD4* 
(n  =  102)  C  vs  P  N  vs A  (P  only) 
CD4 § * 
Percentage  ND  14.0  18.0 
(4.5-23.0)  (13.0-26.0) 
Concentration  ND  200  286 
(cells  per  mm 3)  (38-369)  (180-456) 
3.0  ND  P  <0.0001  ND 
(1.0-7.5) 
21  ND  P  <0.0001  ND 
(7-54) 
Median,  quartiles,  P  values,  and correlation coeffacients (r)  are shown. 
* Measured in frozen BMNC. 
* Measured in fresh BMNC. 
the  patient  group.  The  percentage  and  concentration  of 
CD3  +  cells were lower  in the AIDS  group  compared  to  the 
non-AIDS  group  (Table  3).  The  percentage  and  concentra- 
tion of CD4  §  cells were,  as expected,  reduced  in the AIDS 
group  compared  to the non-AIDS  group,  and it appears that 
the freezing procedure  did not  influence the CD4  count  in 
either of the patient groups  (Table 3). The differences in lym- 
_phocyte  subpopulations  between  AIDS  and  non-AIDS  pa- 
tients  were  also  found  when  patients  in  CDCII+III  were 
compared  with  patients  in CDCIV,  except  that  there were 
Table  4.  Correlation between NK and LAK Cell Activity and Lymphocyte Subsets in Pe@heral Blood 
%  of  %  of  %  of  %  of  %  of  %  of 
CD16 +  CD56 +  CD16+CD56  +  CD16+CD8  +  CD8 §  CD4 +* 
cells  cells  cells  cells  cells  cells 
NK  cell  activity  (C)  P  <0.001  p  =  0.006 
(unstimulated)  r  =  0.39  r  =  0.27 
(p)  P  <o.ool  P  <o.ool 
r  =  0.23  r  =  0.33 
NK  cell  activity  (C)  P  =  0.001  P  =  0.03 
(IL-2  stimulated)  r  =  0.33  r  =  0.22 
(P)  P  <0.001  P  <0.001 
r  =  0.25  r  =  0.34 
NK  cell  activity  (C)  P  <0.001  P  =  0.02 
(IFN-c~  stimulated)  r  =  0.43  r  =  0.23 
(P)  P  <0.001  P  <0.001 
r  =  0.26  r  =  0.36 
LAK  cell  activity 
P  <0.001  P--  0.9  P  =  0.06  P  =  0.002 
r  =  0.36  r  --  -0.01  r  =  -0.19  r  =  -0.31 
P  <0.001  P  -~  0.3  P  =  0.1  P  =  0.9 
r  =  0.40  r  =  0.06  r  =  -0.09  r  =  0.00 
P  <0.001  P  =  0.2  P  =  0.007  P  =  0.004 
r  =  0.36  r  ~  -0.12  r  =  -0.27  r  =  -0.29 
P  <0.001  P  =  0.2  P  =  0.06  P  =  0.4 
r  =  0.41  r  =  0.08  r  =  -0.12  r  =  0.05 
P  <0.001  P  ~=  1.0  P  =  0.008  P  =  0.006 
r  =  0.37  r  =  0.00  r  =  -0.27  r  =  -0.28 
P  <0.001  P  =  0.1  P  <0.001  P  =  0.03 
r  =  0.44  r  =  0.11  r  =  -0.22  r  =  0.15 
(C)  P  =  0.2  P  =  0.4  P  =  0.4  P  =  0.6  P  =  0.9  P  =  0.1 
r  =  0.14  r  =  0.08  r  =  0.08  r  =  0.04  r  =  -0.01  r  =  -0.16 
(P)  P  =  0.06  P  <0.001  P  <0.001  P  =  0.1  P  =  0.3  P  =  0.2 
r  =  0.12  r  =  0.29  r  =  0.29  r  =  -0.14  r  =  -0.07  r  =  0.08 
Results of correlation analyses P  values and correlation coefficients (r)  are shown. All  NK/LAK cell  activities are at  an E/T  ratio  50:1. 
* Measured in fresh BMNC  for patients and in frozen BMNC in controls. 
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Plasma of HIV.infected Patients 
HIV 
antigen  titer  /~2-Microglobulin  IgG  IgA  IgM 
NK cell  activity  P  =  0.8  P  =  0.4  P  =  0.4  P  =  0.2  P  =  0.9 
(unstimulated)  r  =  0.01  r  =  -0.06  r  =  -0.06  r  =  0.07  r  =  0.01 
NK cell activity  P  =  0.9  P  =  0.2  P  =  0.2  P  =  0.7  P  =  0.9 
(IL-2 stimulated)  r  =  0.00  r  =  -0.08  r  =  -0.09  r  =  0.02  r  =  0.01 
NK cell  activity  P  =  0.7  P  =  0.002  P  =  0.1  P  =  0.4  P  =  1.0 
(IFN-a stimulated)  r  =  -0.04  r  =  -0.21  r  =  -0.10  r  =  -0.06  r  =  0.00 
LAK cell activity  P  =  0.4  P  =  0.002  P  =  0.1  P  =  0.4  P  =  0.7 
r  =  -0.05  r  =  -0.19  r  =  -0.10  r  =  -0.05  r  =  -0.02 
Results of correlation analyses P values and correlation coeffacients (r) are shown. 
ND, not done. All NK/LAK cell activities are at E/T ratio 50:1. 
no  differences  in  concentrations  of  CD56"  and  CD16 § 
CD56 +  cells  between  these  two  patient  groups  (data  not 
shown). 
Correlation Analysis.  For patients,  an inverse correlation 
was found between  the percentage of CD4 § cells and per- 
centages of all  NK cell subtypes and CD8 §  cells,  whereas 
there was no correlation between  the percentage of CD4 + 
cells and the total number of any NK cell subtypes or CD8 § 
cells,  (Table  3)  and  no correlation between  the  percentage 
of CD4 §  cells  and  the  proportions  of CD16 §  NK  cells 
coexpressing CD8 or CD56 (data not shown). The percentage 
of CD4 § cells correlated to percentage and total number of 
CD3 + cells  (Table  3). 
To examine the mechanisms behind the suppressed NK and 
LAK cell activity in patients,  the unstimulated  NK cell ac- 
tivity E/T ratio 50:1, the ILo2- and IFN-c~-stimulated NK 
cell activity, and the LAK cell activity E/T ratio 50:1 were 
correlated  to  proportions  of the  different  NK  cell  subsets 
(CD16 +,  CD56 §  CD56+CD16 +,  CD16+CD8 §  for pa- 
tients and controls (Table 4). A positive correlation was found 
between the unstimulated  as well as the IL-2- and IFN-c~- 
stimulated  NK cell activity and the percentages of CD16 § 
CD56 §  and CD16 § CD56 § cells in both groups, whereas 
there was no correlation to the percentage of CD16 § CD8 + 
cells in either group.  In the controls, the LAK cell activity 
did not correlate to any of the NK cell subsets.  In the pa- 
tients,  the LAK cell activity positively correlated to the per- 
centages of CD56 + cells  and CD16 +  CD56 + cells (Table  4). 
In patients, a weak positive correlation was found between 
IFN-ot-stimulated  NK  cell  activity  and  the  percentage  of 
CD4 + cells  (r  =  0.15),  whereas  the unstimulated  NK cell 
activity E/T ratio 50:1, the IL-2-stimulated NK cell activity, 
and the LAK cell activity E/T ratio  50:1 did not correlate 
tO the percentage of CD4 § cells (Table 4). The relationships 
between NK/LAK cell activity and the percentage of CD4 + 
cells were analyzed separately in patients with AIDS and pa- 
tients  without  AIDS.  In  non-AIDS  patients,  the  IFN- 
or-stimulated NK cell activity did correlate with the percentage 
ofCD4 + cells (r  --  0.19, P  =  0.009); this correlation, how- 
ever, was not found in AIDS patients (data not shown). The 
unstimulated  and Ib2-stimulated  NK cell activity and the 
LAK  cell  activity  did  not  correlate  to  the  percentage  of 
CD4 §  cells  in  neither  group  (data  not  shown).  The  un- 
stimulated  NK cell activity per NK cell (LU15/106  CD16 § 
cells and LUls/106 CD56 + cells) did not correlate with the 
percentage of CD4 + cells in patients  (data not shown).  In 
contradiction  to this,  a negative correlation was found be- 
tween  the  NK cell activity,  either  unstimulated  or stimu- 
lated by IL-2 or IFN-c~, and the percentage of CD4 + cells 
in controls, whereas no correlation was found between LAK 
cell  activity  and  the percentage  of CD4 +  cells  (Table 4). 
The NK cell activity,  either unstimulated  or stimulated 
with ILo2  or IFN-ot, and the LAK cell activity did not corre- 
late to the HIV antigen titer,  IgG, IgA, or IgM in patients 
(Table  5).  A  weak  inverse  correlation  was  found between 
32-microglobulin  titer  and  IFN-ot-stimulated  NK cell  ac- 
tivity or LAK cell activity (r  =-0.21 vs r  =  -0.19; Table 5). 
The  relationship  of NK/LAK  cell  activity  with  other 
parameters was further analyzed in patients with AIDS and 
patients without AIDS, as well as in controls, by means of 
multiple linear regression. The square roots of the unstimu o 
lated NK cell activity (E/T ratio 50:1), the IL-2- and IFN- 
or-stimulated NK cell activity, and the LAK cell activity (E/T 
ratio 50:1) were included in the models as dependent parameters 
in patients and controls. The square roots of the dependent 
parameters  were used to obtain normal distribution  of the 
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Independent  Coefficients of  P  values of 
variable  Dependent  variables  dependent  variables  dependent  variables 
NK cell activity  (C)  %  of CD4 + cells  -0.028  _+  0.018  0.1 
(unstimulated)  %  of CD16 §  cells  0.069  _+  0.025  0.007 
%  of CD56 + cells  0.030  -+  0.040  0.5 
(N) 
(A) 








LAK cell activity  (C) 
(N) 
%  of CD4 §  cells  0.018  -+  0.010  0.08 
%  of CD16 §  cells  0.014  _+  0.014  0.2 
%  of CD56 §  cells  0.071  _+  0.015  0.00001 
%  of CD4 §  cells  -0.006  _+  0.027  0.8 
%  of CD16 §  cells  -0.040  _+  0.022  0.07 
%  of CD56 §  cells  0.058  _+  0.025  0.02 
%  of CD4 §  cells  -0.032  _+  0.023  0.2 
%  of CD16 §  cells  0.072  +  0.031  0.02 
%  of CD56 §  cells  0.027  +  0.052  0.6 
%  of CD4 §  cells  0.038  _+  0.014  0.07 
%  of CD16 §  cells  0.015  _+  0.019  0.4 
%  of CD56 §  cells  0.078  _+  0.020  0.0002 
%  of CD4 + cells  -0.029  _+  0.041  0.5 
%  of CD16 §  cells  -0.043  _+  0.032  0.2 
%  of CD56 §  cells  0.092  _+  0.047  0.06 
%  of CD4 §  cells  -0.024  _+  0.021  0.3 
%  of CD16 + cells  0.097  _+  0.030  0.002 
%  of CD56 §  cells  0.015  _+  0.050  0.8 
%  of CD4 §  cells  0.058  +  0.014  0.00004 
%  of CD16 §  cells  0.021  _+  0.019  0.3 
%  of CD56 + cells  0.100  +  0.020  <0.00001 
%  of CD4+  cells  -0.018  _+  0.038  0.6 
%  of CD16 + cells  -0.035  +  0.029  0.2 
%  of CD56 §  cells  0.067  +  0.043  0.1 
%  of CD4 + cells  -0.025  -+  0.019  0.2 
%  of CD16 §  cells  0.006  _+  0.029  0.8 
%  of CD56 + cells  0.019  _+  0.044  0.7 
%  of CD4 §  cells  0.038  -+  0.016  0.05 
%  of CD16 §  cells  -0.026  +-  0.021  0.2 
%  of CD56 §  cells  0.121  +  0.023  <0.00001 
continued 
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Independent  Coefftdents  of  P  values of 
variable  Dependent  variables  dependent  variables  dependent  variables 
(A)  %  of CD4 § cells  -0.037  +_ 0.047  0.4 
%  of CD16 § cells  0.000  _  0.038  1 
%  of CD56 + cells  0.013  +  0.050  0.8 
Results of multiple linear regression: parameters included in models, their coei~cients  _+  SE, and P values of the parameters in F test are shown. 
Independent variables were transformed by taking the square root before they were included in the models. All NK/LAK cell activities are at E/T 
ratio 50:1. 
residuals.  The dependent variables in each group were the 
percentages  of CD4+,  CD16+,  and  CD56 +  cells.  In  pa- 
tients, the following additional independent parameters were 
included in the model:  HIV antigen titer,  IgA, IgG, IgM, 
and B2-microglobulin. These additional dependent parame- 
ters were all insignificant  in models including  the percen- 
tages of CD4 + , CD16 + , and CD56 + cells. It appears from 
Table 6 that regarding the NK cell activity in controls (un- 
stimulated or stimulated by I1-2 or IFN-c~),  the percentage 
of CD16 + cells contributed the most to the variation in cy- 
totoxicity, whereas the percentages of CD56 + and CD4 cells 
were without significant  effect. However, in patients without 
AIDS,  the percentage of CD56 + cells,  not  the percentage 
of  CD16 +  cells,  explained  the  variation  in  cytotoxicity 
(Table  6).  In  patients  without  AIDS,  the  percentage  of 
CD4 + cells also had a significant effect on the IFN-ot-stim- 
ulated NK cell activity and the LAK cell activity (Table 6). 
In AIDS patients,  however, the percentages of CD4 + and 
CD16 +  cells  had  no  influence  on NK/LAK cell activity, 
whereas  the  percentage  of CD56 +  cells  had  a  significant 
effect on the unstimulated NK cell activity, but no influence 
on the stimulated  NK and LAK cell activities  (Table  6). 
In patients,  a strong correlation was found between the 
LAK cell activity and the NK cell activity, either unstimu- 
lated or stimulated with IFN-ot or II,-2 (r =  0.46, P <0.001, 
r  --  0.58, P <0.001, r  =  0.53, P <0.001, respectively; E/T 
ratio 50:1),  whereas in controls, this correlation was weaker 
(r  =  0.27,  P  =  0.009,  r  =  0.32,  P  =  0.002,  r  =  0.39, 
P  <0.001,  respectively). 
Discussion 
Knowledge about the percentual distribution of NK cells 
among BMNC is important to evaluate the functional in vitro 
NK cell assay, in which fixed numbers of BMNC are studied. 
However, knowledge about the total concentration  of NK 
cells is important  to evaluate the NK cell activity in vivo. 
This study shows that in HIV-seropositive patients, the per- 
centages of all NK cell subtypes are elevated or not differ- 
ent  from  that  of controls.  Since the  fractions  of CD16 § 
CD56 +, and CD16+56 + cells were not decreased,  the defec- 
tive in vitro NK cell activity (lysis per fixed number of BMNC) 
in HIV-seropositive subjects must be caused by a defective 
lytic capacity of each NK cell, as suggested by others (5, 8, 
11, 21). Pearson correlation analysis revealed that the NK cell 
activity correlated to the percentages of CD16*,  CD56 +, 
and CD16+CD56 + cells in patients  and controls,  but not 
to the CD16+CD8 + cell subgroup,  which is in line with 
the assumption that the majority of human NK cell activity 
is  mediated by' the  CD16 +,  CD56 §  and  CD16+CD56 + 
cells  (18).  However, through  multiple linear  regression,  it 
was concluded that  in controls,  the percentage  of CD16 + 
cells was the only parameter tested with any significant effect 
on NK cell activity, whereas in patients,  the percentage of 
CD16 + cells had almost no effect on NK cell activity. These 
results  could  indicate  that  a  specific  defect  exists  in  the 
CD16 + cell population  in subjects with HIV infection.  If 
the cytotoxic function of these cells declines, the importance 
of the CD56 + cells increases.  This could explain the finding 
that  the LAK cell activity correlated to the percentages of 
CD56 + and CD16 + CD56 + cells only in the patient group. 
However, others have reported a correlation in LAK cell ac- 
tivity to the percentage of CD56 + cells in HIV-seropositive 
patients, as well as in healthy HIV-seronegative individuals 
(13),  but since the percentage of CD56 + cells was not de- 
creased in the present study's patients, low fractions of this 
subpopulation could not explain the depressed in vitro LAK 
cell activity in HIV infection. 
Our findings agree with studies showing normal percen- 
tages of CD16 + (10) or CD56 + cells  (13),  whereas others 
have  shown  that  the  percentages  of CD16 +  and  CD16 + 
CD8 + NK cells were low in HIV-seropositive subjects (6, 
22). The function of NK cells in HIV-seropositive subjects 
differed from that of controls in their responsiveness to IFN-ct. 
The patients' NK cells were boosted with IFN-ct to a lesser 
degree than  cells  of controls,  in accordance with previous 
studies (8,  23),  whereas I1-2 boosted the NK cell activity 
to the same degree in both groups, but without restoration 
of the defective cytotoxic activity in patients as suggested by 
others (9, 11). It has been suggested that a serum factor con- 
tributes to the suppression of the NK and LAK cell func- 
tions, but this factor has not been fully identified (16,  24, 
25). Our study showed that there was no correlation between 
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HIV antigen  in  serum. 
Some studies have shown that the NK (8) and LAK (16) 
cell activities in HIV-seropositive subjects decrease with dis- 
ease progression. Others were unable to show differences in 
cytotoxicity between AIDS-rdated complex and AIDS pa- 
tients (10,  11). Our study showed that NK cell activity, ei- 
ther unstimulated or stimulated,  and LAK cell activity did 
not differ between the AIDS group and the non-AIDS group. 
Furthermore,  the NK and LAK cell activities did not differ 
between patients with disseminated CMV infection, malig- 
nant  lymphoma,  or Kaposi's  sarcoma,  compared  to  those 
without these AIDS-defining disorders. However, when the 
CDC classification system was used, it revealed  a difference 
between CDCII + III and CDCIV in IFN-ot-stimulated NK 
cell activity and LAK cell activity. The interpretation of these 
results is that  the defect in these two forms of stimulated 
cytotoxicity is progressive until the early symptomatic stage 
of HIV infection, whereas no further progression is seen by 
the onset of overt AIDS. In line with these observations, there 
was a positive effect on IFN-oe-stimulated NK cell activity 
and LAK cell activity by the percentage of CD4 + cells  in 
multiple linear regression in patients without AIDS.  None 
of the other classical progression markers,  including IgG, IgA, 
HIV antigen, and B2-microglobulin were of any importance 
for NK/LAK cell activity when tested in a model including 
the percentages of CD4 +, CD16 +, and CD56 + cells. This, 
combined with the fact that the effect of the percentage of 
CD4 cells on NK/LAK cell activity is only seen in patients, 
indicates  that  the  loss  of CD4 +  cells  could have a direct 
influence on the decrease in NK/LAK cell activity in HIV 
infection. The fact that IFN-c~-stimulated NK cell activity 
and  LAK cell activity  are correlated  to  the percentage  of 
CD4 §  cells  and  are  different  between  CDCII+III  and 
CDCIV  NK cell activity indicates  that  the defect in HIV 
disease of these two measures of natural immunity is more 
specific and of greater importance compared to, e.g., the un- 
stimulated and IL-2-stimulated  NK cell activity.  Not only 
the loss of CD4 + cells, but also changes in the function of 
these cells, could contribute to the defective natural immu- 
nity in HIV disease. The important finding of an imbalance 
in the Thl-  and Th2-type responses that contribute to the 
loss of T  cell response to recall antigens and, finally,  loss of 
reactivity to mitogens (26) may be extended to also include 
a loss of non-MHC-restricted  cytotoxic activity. 
The finding of a lower CD16 + cell count in patients com- 
pared to controls is in accordance with the findings of Man- 
sour et al.  (6).  However, the finding that the concentration 
of the CD16+CD8 + subgroup was elevated in patients com- 
pared to controls is in contrast to the findings by Mansour 
et al.  (6),  who described a selective depletion  of this  sub- 
group.  In accordance with  previous findings  (6,  8) all the 
NK cell subsets had a higher percentage, but a lower total 
cell count in the AIDS group compared to the non-AIDS 
group. The mechanisms behind the loss or decreased produc- 
tion of NK cells are not understood.  It has been suggested 
that HIV can infect NK cells (7, 27, 28), whereas other studies 
report only nonproductive HIV infection of NK cells (29). 
Active in vitro HIV infection of NK cells after infection with 
human  herpesvirus 6 has been described (30).  The present 
study shows that the lower NK cell count is determined by 
a lower total lymphocyte count in the AIDS patients.  This 
might  be related to a weakened bone marrow  function  in 
AIDS patients  (reviewed in 31). 
The results presented in this paper have been obtained by 
the use of frozen cells. Since freezing did not affect the FACS  | 
analysis of lymphocyte subsets, and since it had the same effect 
on NK cell activity in patients  and controls,  as well as in 
AIDS and non-AIDS patients, it is unlikely that the conclu- 
sions of this paper are to any major extent influenced by the 
use of frozen cells. 
We conclude that  the non-MHC-restricted  cytotoxicity 
is impaired in HIV patients primarily because of a qualitative 
defect of the NK and LAK cells.  This study dearly shows 
an early defect in NK/LAK cell activity in HIV infection, 
which for the unstimulated NK cell activity, does not prog- 
ress  by onset  of symptoms.  However,  the  defect in  IFN- 
a-stimulated NK and LAK cell activities is, however, progres- 
sive until the onset of symptoms, and it is related to the loss 
of CD4 + cells. 
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